Nuclear receptor subfamily 4 group A member 2 (NR4A2) is an orphan nuclear receptor that is over-expressed in cancer and promotes cell proliferation, migration, transformation, and chemoresistance. Increased expression and function of NR4A2 have been attributed to various signaling pathways, but little is known about microRNA (miRNA) regulation of NR4A2 in cancer. To investigate the posttranscriptional regulation of NR4A2, we used a 3′ untranslated region (UTR) reporter screen and identified miR-34 as a putative regulator of NR4A2. By using computer predictions, we identified and confirmed an miRNA recognition element in the 3′ UTR of NR4A2 that was responsible for miR-34–mediated suppression. We next demonstrated that overexpression of exogenous miR-34 or activation of the p53 pathway, which regulates endogenous miR-34 expression, decreased NR4A2 expression. Consistent with previous reports, overexpression of NR4A2 blocked the induction of p53 target genes, including mir-34a. This was a phenotypic effect, as NR4A2 overexpression could rescue cells from p53-induced inhibition of proliferation. In summary, our results are the first characterization of a cancer-related miRNA capable of regulating NR4A2 and suggest a network and possible feedback mechanism involving p53, miR-34, and NR4A2.
Aflatoxins are produced by the fungi Aspergillus flavus and Aspergillus parasiticus and are common food contaminants in tropical developing countries. Extensive aflatoxin consumption has been shown to be highly associated with liver disease. A case-control study was conducted to determine the association between aflatoxin and liver disease in Kumasi, Ghana. A questionnaire was administered to examine socio-demographic characteristics and food storage and consumption practices, and urine samples were collected to measure levels of the aflatoxin metabolite (AFM1). Two hundred and seventy-six people participated in the study; 38 had liver disease (cases), 136 had neither hepatitis B/C nor liver disease (negative controls), and 102 were hepatitis B/C positive without liver cancer (positive controls). A much higher percent of participants in each group was male (76% of cases, 88% of negative controls and 65% of positive controls). Multivariate analysis showed that age was a significant predictor for being a case when cases were compared to negative controls. The odds of being a case was 70% less for participants aged 25–34 years (odds ratios (OR) 0.30; 95% confidence interval (CI) 0.10–0.88) compared to those ≥45 years. For cases; Akans were seven times more likely to have AFM1 levels below the median when compared to other ethnic groups (OR 7; CI 1.41–34.68). When cases were compared to positive controls, they were 2.29 times more likely to report awareness of aflatoxin contamination of groundnuts (95% CI 1.06–4.91). Cases were also two times more likely to report awareness of aflatoxin contamination of maize than all controls combined (95% CI 1.02–4.11). However, most cases reported that aflatoxin contamination does not cause sickness in humans. This shows that there is awareness of aflatoxin contamination without proper understanding of the serious potential adverse health impacts among these study participants. These findings indicate that educational interventions that stress the harmful health effects of aflatoxin in food, with an emphasis on the higher risk for males, are urgently needed. The reasons for lower aflatoxin levels among Akans need to be determined, and the findings used to design interventions that benefit other ethnic groups in the society.
Nuclear receptor (NR) subfamily 4 member 2 (NR4A2), also known as Nurr1, has been shown to have oncogenic properties, in which it can mediate cell transformation, migration and drug resistance. However, the manner in which Nurr1 mediates these cancer-promoting features is not completely understood, but research implicates p53 as a potential intermediary. In this study, we show that Nurr1 enhances the proliferative rate of colorectal cancer cells. This increase in cell growth is accompanied by an upregulation of cyclin D3, a putative target gene of Nurr1. To understand how Nurr1 itself is regulated, we performed a reporter screen to identify microRNA regulators of Nurr1's 3’UTR. We identified miR-34c as a putative regulator of Nurr1 and this direct regulation was confirmed through site-directed mutagenesis of the predicted seed region. We next determined if p53 activation could affect Nurr1 expression through transcriptional activation of miR-34. Using Nutlin-3a to activate p53, we found that Nurr1 expression decreased in a dose response manner. Lastly, we sought to determine if Nurr1 could attenuate p53 activation. We found that overexpression of Nurr1 in colorectal cancer cells caused an attenuation of p53 transactivation of target genes following Nutlin-3a treatment. Our results suggest that a p53-miR-34-Nurr1 regulatory network exists, which would allow p53 to maintain Nurr1 in a suppressed state through miR-34-mediated regulation and prevent tumorigenesis. In cases of p53 mutation or Nurr1 overexpression, this network would be compromised, allowing Nurr1 to enhance tumorigenesis or drug resistance. Citation Format: Jordan A. Beard, Justin L. Hills, Alexa Tenga, Apana A. Takwi, Taosheng Chen. Nuclear receptor Nurr1 mediates cell proliferation and is involved in a p53-microRNA-34 regulatory network. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3393. doi:10.1158/1538-7445.AM2014-3393
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.